Home / Pharmaceuticals / Heparin Market By Product (Unfragmented Heparin, Low Molecular Weight Heparin and Ultra-Low Molecular Weight Heparin), By Route of Administration (Subcutaneous and Intravenous) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Heparin Market By Product (Unfragmented Heparin, Low Molecular Weight Heparin and Ultra-Low Molecular Weight Heparin), By Route of Administration (Subcutaneous and Intravenous) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Published: Jan 2018 | Report Code: 58943-01-18

The International Society on Thrombosis and Hemostasis 2017 report has stated the global incidence rate of venous thromboembolism to be 2 per 1000 persons. The risk factors associated with venous thromboembolism are prolonged hospital stay, cancer chemotherapy, smoking, alcohol consumption and pregnancy. Heparin has excellent plasma protein binding properties. It has been found to be effective in treatment of Parkinson’s disease via the cathepsin-d activity. Heparin being a glycosaminoglycan has been found to reduce inflammation in rheumatoid arthritis and acute pancreatitis. 

The report titled heparin market covers product segment including unfragmented heparin, low molecular weight heparin and ultra-low molecular weight heparin. The route of administration comprises subcutaneous and intravenous. Data forecast and market estimation is covered to understand the latest trend in the products and route of administration segment. 

Country cross sectional analysis is covered for the major countries enlisted in the 5 major geographical regions:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size and data forecast are covered in the geography segment to understand the attractive investment proposition by geography.

Company profiles covers important information such as recent news coverage, business information and product portfolio. Product portfolio gives a clear understanding the recent trend present in the heparin market. Recent news covers the latest launch of value added heparin product and technological development in the production of synthetic heparin. Market assessment and data forecast elucidates the existing business milieu in global heparin market. The ace players involved in the production of heparin are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Heparin Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Heparin Market Portraiture
2.1.1. Global Heparin Market, by Product, 2016 (Value %)
2.1.2. Global Heparin Market, by Route of Administration, 2016 (Value %)
2.1.3. Global Heparin Market, by Geography, 2016 (Value %)

Chapter 3. Heparin Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Heparin Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape : Global Heparin Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Heparin Market, by Product, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Heparin Market, by Product, 2016
4.3. Unfractionated Heparin
4.4. Low Molecular Weight Heparin
4.5. Ultra-Low Molecular Weight Heparin

Chapter 5. Global Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Heparin Market, by Route of Administration, 2016
5.2. Subcutaneous
5.3. Intravenous

Chapter 6. Global Heparin Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Heparin Market Analysis, 2015 – 2025
6.2.1. North America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.2.2. North America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.2.3. North America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Heparin Market Analysis, 2015 – 2025
6.3.1. Europe Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.3.2. Europe Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.3.3. Europe Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Heparin Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of Asia Pacific
6.5. Latin America Heparin Market Analysis, 2015 – 2025
6.5.1. Latin America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa Heparin Market Analysis, 2015 – 2025
6.6.1. Middle East and Africa Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.6.2. Middle East and Africa Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.6.3. Middle East and Africa Heparin Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East and Africa

Chapter 7. Company Profiles
7.1. Aspen Holdings
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Baxter International, Inc.
7.3. B. Braun Melsungen AG
7.4. Dr. Reddy’s Laboratories Ltd.
7.5. Fresenius SE & Co. KGaA
7.6. Leo Pharma A/S
7.7. Pfizer, Inc.
7.8. Sanofi AG
7.9. Syntex S.A.
7.10. Teva Pharmaceutical Industries Ltd.

List of Tables

TABLE 1 Global Heparin Market Portraiture
TABLE 2 Global Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 3 Global Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 4 Global Heparin Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 6 North America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 7 North America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Europe Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 10 Europe Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Asia Pacific Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 12 Asia Pacific Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 13 Asia Pacific Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 15 Latin America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 16 Latin America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 17 Middle East and Africa Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 18 Middle East and Africa Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 19 Middle East and Africa Heparin Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 20 Aspen Holdings: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Baxter International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 B.Braun Melsungen AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Dr. Reddy’s Laboratories Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Fresenius SE & Co. KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 LEO Pharma A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Sanofi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Syntex S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List of Figures

FIG. 1 Heparin: Market Segmentation
FIG. 2 Global Heparin Market Share, by Product, 2016 (Value %)
FIG. 3 Global Heparin Market Share, by Route of Administration, 2016 (Value %)
FIG. 4 Global Heparin Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Unfragmented Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Low Molecular Weight Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Ultra-Low Molecular Weight Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Subcutaneous Route of Administration Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Intravenous Route of Administration Market, 2015 – 2025 (US$ Mn)
FIG. 12 U.S. Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 13 Canada Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 14 U.K. Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 15 Germany Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 16 Rest of Europe Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 17 Japan Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 18 China Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 19 India Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 20 Rest of Asia Pacific Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 21 Brazil Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 22 Mexico Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 23 Rest of Latin America Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 24 GCC Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 25 Rest of Middle East and Africa Heparin Market, 2015 – 2025 (US$ Mn)

Based on product, the global heparin market is categorized into:

  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Ultra-Low Molecular Weight Heparin

 

Heparin Market

Heparin is an anticoagulant prescribed for the treatment of venous complications such as arterial thromboembolism, deep vein thrombosis and pulmonary embolism. It is produced by the mast cells and basophils and binds to the enzyme antithrombin III and further causes inactivation of blood clotting factor thrombin. Heparin is produced from the mucosal tissues of slaughtered porcine and bovine. It is present in the World Health Organization list of essential medicines which depicts its importance in the treatment. The low molecular weight represents the largest market share in the products segment due to its enhanced bioavailability and less subcutaneous dosing frequency for complication like venous thromboembolism. Additionally the most important advantage of low molecular weight heparin is reduced risk of heparin induced thrombocytopenia. On the other hand, Ultra-low molecular weight heparin has enhanced safety and efficacy due to its structural configuration promoting depolymerization. Increasing demand as a therapeutic agent providing thromboprophylaxis in cancer patients undergoing surgery drives the medicinal application of ultra-low molecular weight heparin. Top players in heparin market are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on route of administration, the heparin market is categorized into:

  • Subcutaneous
  • Intravenous

Heparin Market

The biological half-life of fragmented heparin is 1-2 hours after infusion and low molecular weight heparin has half-life 4 times more than fragmented heparin. Proper caution needs to be taken while considering the dose specifications of heparin as there are severe side effects of overdose. Protamine sulphate has been useful to a certain extent to reverse the heparin overdose effect but logically it is not possible to determine the blood concentration of heparin owing to its excellent plasma protein binding. Subcutaneous route is the most preferred route owing to its enhanced safety, less administration time and relatively available at lower cost. It is useful in pregnant women having increased risk for venous thromboembolism and patients undergoing reproductive immunology treatment. Intravenous route of administration has advantages such as to fast onset of action and is the most preferred route of choice in open heart surgeries, kidney dialysis and blood transfusion.

For the purpose of this study, the global heparin market is categorized into the following regional and country specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Heparin Market

National Center on Birth Defects and Developmental Disabilities has cited that every year in the United States around 900,000 people suffer with venous thromboembolism DVT/PE having a prevalence of 1 to 2 per 1,000 person. Approximately 10% to 30% citizens die after a month of diagnosis and death due to venous thromboembolism is the number one cause in about 25 % of the patients suffering with DVT/PE. North America owns the largest market share in heparin products due to increasing number of patients suffering with DVT/PE and presence of top players actively engaged in the research and development of heparin products. According to European Union statistics the rising prevalence of coagulation disorders results in death of approximately half a million E.U. citizens each year. Additionally the supportive regulatory environment created by European Medical Agency for synthetic heparin products provide thrust to the European heparin market growth. Asia Pacific will register a remarkable growth in heparin products as the patent expiry of low molecular weight heparin will boost the generic market. World Health Organization has stated that the major cause of death in Asia Pacific regarding clotting disorders is pulmonary embolism.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients